Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

NTLA vs TWST: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TWST Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 6–2 Matrix Metrics)

TWST Overall Winner 6-Pillar Tally: NTLA 0 – 6 TWST Matrix Metrics: NTLA 2 – 6 TWST

As of Nov 16, 2026, Twist Bioscience Corporation (TWST) is the stronger overall head-to-head candidate over Intellia Therapeutics, Inc (NTLA) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NTLA carries a Unified Composite Score of 49.9/100 (HOLD) at $10.00 (N/M Forward P/E, -826.0% operating margin), whereas TWST carries 51.7/100 (HOLD) at $105.85 (N/M Forward P/E, -31.9% operating margin).

  • Technical & Structure Timing Caution: NTLA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.3); meanwhile TWST trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 35.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About NTLA vs TWST
NTLA NASDAQ
Intellia Therapeutics, Inc
In Vitro & In Vivo Diagnostic Substances
$10.00
+3.09% 1D
Market Cap $1.5B
TTM Revenue $53M
Forward P/E N/M
Beta / 30D Vol 2.30β · 87% Vol
Unified Composite Score
49.9 / 100 HOLD
Tech 47.0 Fund 55.0 Flow 59.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.1%), weak momentum, RSI 39
RSI-14: 39.3 · SMA20: $11.58 · SMA50: $11.86
TWST NASDAQ Head-to-Head Winner
Twist Bioscience Corporation Common Stock
Biological Products, (No Disgnostic Substances)
$105.85
-5.15% 1D
Market Cap $7.6B
TTM Revenue $432M
Forward P/E N/M
Beta / 30D Vol 3.15β · 127% Vol
Unified Composite Score
51.7 / 100 HOLD
Tech 40.0 Fund 56.0 Flow 68.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 36
RSI-14: 35.9 · SMA20: $137.33 · SMA50: $149.84

6-Pillar Scorecard Institutional Category Breakdown (NTLA 0 – 6 TWST)

Columns: Metric · NTLA · TWST
1. Valuation Multiples TWST
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 29.1x 17.5x
2. Growth & Scale TWST
Revenue Growth (YoY) -48.0% +23.2%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $53M $432M
Market Cap $1.5B $7.6B
3. Profitability & Quality TWST
Gross Margin N/A 52.0%
Operating Margin -826.0% -31.9%
Net Profit Margin 0.0% -31.7%
Return on Equity (ROE) -62.6% -29.6%
4. Balance Sheet & Cash Flow TWST
Cash Generation (TTM) -$358M -$115M EBITDA
Cash Flow Margin N/A -26.7% EBITDA Mgn
Net Cash / Leverage $74M Net Debt (0.38x D/E) $7.11 Book/Sh · -29.6% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning TWST
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 101.3% (78th %ile) 93.2% (18th %ile)
Put/Call OI Skew 0.42x (Call-Skewed) 1.04x (Balanced)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat TWST
OpEx & R&D Intensity N/A 83.9% of Rev ($362M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: NTLA (2) vs TWST (6)
Institutional Metric NTLA TWST Criterion Row Edge
Market Capitalization
Scale
$1.5B $7.6B Larger Scale TWST
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-48.0% +23.2% Higher Growth TWST
Operating Margin (TTM)
Profitability
-826.0% -31.9% Higher Margin TWST
Net Profit Margin
Profitability
0.0% -31.7% Higher Margin NTLA
Return on Equity (ROE)
Capital Efficiency
-62.6% -29.6% Higher ROE TWST
52-Week Range Position
Momentum
20% ($8–$18) 42% ($23–$220) Stronger Trend TWST
Beta / 30D Volatility
Risk Regime
2.30β · 87% Vol 3.15β · 127% Vol Lower Realized Risk NTLA
Unified Institutional Score
Composite Signal
49.9 / 100 (HOLD) 51.7 / 100 (HOLD) Higher Composite TWST
Trailing 12M Revenue (USD)
Operating Scale
$53M $432M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 52.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 29.1x EV/Rev N/M PEG · 17.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$358M ($74M Net Debt (0.38x D/E)) -$115M EBITDA ($7.11 Book/Sh · -29.6% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NTLA +7.83 pp
NTLA: -12.43% · TWST: -20.26%
3M Horizon TWST +4.96 pp
NTLA: -13.79% · TWST: -8.83%
6M Horizon TWST +133.79 pp
NTLA: -21.2% · TWST: +112.59%
1Y Horizon TWST +238.67 pp
NTLA: +15.34% · TWST: +254.01%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period NTLA Revenue TWST Revenue NTLA Op. Margin TWST Op. Margin Margin Leader
FY2018 $30M $30M -298.6% -277.5% TWST
FY2019 $40M $50M -246.8% -200.1% TWST
FY2020 $60M $90M -235.5% -155.5% TWST
FY2021 $30M $130M -810.4% -115.4% TWST
FY2022 $50M $200M -879.0% -115.3% TWST
FY2023 $40M $250M -1420.5% -88.6% TWST
FY2024 $60M $310M -923.1% -70.6% TWST
FY2025 $70M $380M -651.7% -36.2% TWST

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
NTLA BREAKDOWN
94d in phase · OBV DISTRIBUTION
Current IV 101.3%
IV Percentile 78th %ile
Put/Call OI Skew 0.42x (Call-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact NTLA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TWST CONSOLIDATION
69d in phase · OBV DISTRIBUTION
Current IV 93.2%
IV Percentile 18th %ile
Put/Call OI Skew 1.04x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact TWST Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
NTLA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.5B market capitalization and -826.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published · CRISPR / Gene Editing
TWST Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $7.6B market capitalization and -31.9% operating margin.
OpEx & R&D Reinvestment 83.9% of Rev ($362M)
90D Engineering Disclosures 0 Published · Spatial Genomics

Investor FAQ NTLA vs TWST Key Questions & Quantitative Answers

As of Nov 16, 2026, Twist Bioscience Corporation (TWST) is the stronger overall head-to-head candidate over Intellia Therapeutics, Inc (NTLA) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). NTLA carries a Unified Composite Score of 49.9/100 (HOLD) at $10.00 (N/M Forward P/E, -826.0% operating margin), whereas TWST carries 51.7/100 (HOLD) at $105.85 (N/M Forward P/E, -31.9% operating margin). Technical & Structure Timing Caution: NTLA is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.3); meanwhile TWST trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 35.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TWST leads the Growth & Scale pillar: NTLA posts -48.0% YoY revenue growth and +0.0% YoY earnings growth on $53M TTM revenue (N/A gross margin, -826.0% operating margin), compared with TWST at +23.2% YoY revenue growth and +0.0% YoY earnings growth on $432M TTM revenue (52.0% gross margin, -31.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), NTLA cumulative revenue shifted +133.3% while TWST shifted +1166.7%. In operating R&D and SG&A reinvestment, NTLA deploys N/A (0 90-day corporate R&D disclosures) versus 83.9% of Rev ($362M) (0 disclosures) for TWST.

TWST screens cheaper on headline valuation multiples. NTLA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 29.1x EV/Revenue (unreported FCF margin), whereas TWST trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 17.5x EV/Revenue (-26.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against NTLA (-62.6% ROE) versus TWST (-29.6% ROE) capital efficiency.

In options market volatility and institutional positioning, NTLA carries 101.3% implied volatility (78th %ile, Elevated (60th–80th %ile)), a 0.42x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.30β · 87% Vol realized risk). By comparison, TWST carries 93.2% implied volatility (18th %ile, Compressed (<25th %ile)), a 1.04x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (3.15β · 127% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.